To assess the impact of antipsychotic tapering and discontinuation on measures of metabolic functioning and psychiatric symptom severity in severely impaired youth hospitalized in a psychiatric state hospital.
Methods:
The study examined psychiatric and metabolic measures in 67 hospitalized children and adolescents (mean age 10.0; 56 with discontinued use of antipsychotics, 10 with continued use of antipsychotics, and 1 started on an antipsychotic) from admission to discharge.
Results:
Upon admission, 56 youth were tapered off of antipsychotic medications, started on other forms of pharmacotherapy (92.9% were started on medications used to treat attention-deficit/hyperactivity disorder), and received evidence-based behavioral programming and were ultimately discharged from the hospital. The mean duration of treatment was 228 days for the discontinuation group and 204 days for the continuation group. Significant decreases in body mass index [BMI; t(53) = 7.12, p = 0.0001] and BMI percentile [t(53) = 6.73, p = 0.0001] were found from admission to discharge in the antipsychotic discontinuation group. Changes in BMI, BMI percentile, or systolic blood pressure were not found in the group (n = 10) who were maintained on antipsychotics. Both groups experienced a significant increase in their Global Assessment of Functioning score [t(52) = 19.98, p = 0.0001 for discontinued; t(8) = 5.092, p = 0.001 for maintained]. Psychiatric symptom severity scores significantly improved in many subscales relevant to disruptive behaviors and mood disorders for those who were removed from the medications. For those maintained on the antipsychotics, there were fewer changes in psychiatric symptom scores.
Conclusion:
Discontinuation of atypical antipsychotic medications in conjunction with tailoring treatment to presenting diagnoses resulted in metabolic and psychiatric symptom improvement among severely impaired state hospital inpatient youth. These results serve as a feasibility demonstration that discontinuation of antipsychotics does not provoke psychiatric destabilization, particularly among disruptive behavior disordered youth.
Get full access to this article
View all access options for this article.
References
1.
AkramG: Profiling psychotropic discharge medication from a children's psychiatric ward. Int J Clin Pharm, 37:753–757, 2015.
2.
AlexanderGC, GallagherSA, MascolaA, MoloneyRM, StaffordRS: Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiol Drug Saf, 20:177–184, 2011.
3.
AmanMG, BuksteinOG, GadowKD, ArnoldLE, MolinaBS, McNamaraNK, Rundberg-RiveraEV, LiX, KippH, SchneiderJ, ButterEM, BakerJ, SprafkinJ, RiceRRJr, BangaloreSS, FarmerCA, AustinAB, Buchan-PageKA, BrownNV, HurtEA, GrondhuisSN, FindlingRL: What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder?. J Am Acad Child Adolesc Psychiatry, 53:47–60.e41, 2014.
4.
AndersonRL, LyonsJS, GilesDM, PriceJA, EstleG: Reliability of the Child and Adolescent Needs and Strengths-Mental Health (CANS-MH) Scale. J Child Fam Stud, 12:279–289, 2003.
5.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC: American Psychiatric Association; 2000.
6.
BaezaI, CorrellCU, SaitoE, AmanbekovaD, RamaniM, KapoorS, ChekuriR, De HertM, CarbonM: Frequency, characteristics and management of adolescent inpatient aggression. J Child Adolesc Psychopharmacol, 23:271–281, 2013.
7.
BarbuiC, BighelliI, CarràG, CastellazziM, LuciiC, MartinottiG, NosèM, OstuzziG: Antipsychotic dose mediates the association between polypharmacy and corrected QT interval. PLoS One, 11:e0148212, 2016.
8.
BiedermanJ, PettyC, FaraoneSV, SeidmanL: Phenomenology of childhood psychosis: Findings from a large sample of psychiatrically referred youth. J Nerv Ment Dis, 192:607–614, 2004.
9.
BladerJC: Acute inpatient care for psychiatric disorders in the United States, 1996 through 2007. Arch Gen Psychiatry, 68:1276–1283, 2011.
10.
BubierJL, DrabickDA: Co-occurring anxiety and disruptive behavior disorders: The roles of anxious symptoms, reactive aggression, and shared risk processes. Clin Psychol Rev, 29:658–669, 2009.
CalargeCA, NicolG, SchlechteJA, BurnsTL: Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment. J Child Adolesc Psychopharmacol, 24:120–129, 2014.
13.
ChohanPS, MittalR, JavedA: Antipsychotic medication and QT prolongation. Pak J Med Sci, 31:1269–1271, 2015.
14.
CooperWO, ArbogastPG, DingH, HicksonGB, FuchsDC, RayWA: Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr, 6:79–83, 2006.
15.
CorrellCU, CarlsonHE: Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry, 45:771–791, 2006.
16.
CorrellCU, ManuP, OlshanskiyV, NapolitanoB, KaneJM, MalhotraAK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA, 302:1765–1773, 2009.
17.
DalyDL, SchmidtMD, SpellmanDF, CristeTR, DingesK, TeareJF: The Boys Town Residential Treatment Center: Treatment implementation and preliminary outcomes. Child Youth Care Forum, 24:267–279, 1998.
18.
DeshmukhP, KulkarniG, BarzmanD: Recommendations for pharmacological management of inpatient aggression in children and adolescents. Psychiatry (Edgmont), 7:32–40, 2010.
19.
DilleyJB, WeinerDA, LyonsJS, MartinovichZ: The validity of the child and adolescent needs and strengths assessment. Presented at American Psychological Association's 11th annual convention; Toronto, 2007.
20.
EbertT, MidbariY, ShmilovitzR, KosovI, KotlerM, WeizmanA, RamA: Metabolic effects of antipsychotics in prepubertal children: A retrospective chart review. J Child Adolesc Psychopharmacol, 24:218–222, 2014.
21.
GadowKD, BrownNV, ArnoldLE, Buchan-PageKA, BuksteinOG, ButterE, FarmerCA, FindlingRL, KolkoDJ, MolinaBS, RiceRRJr, SchneiderJ, AmanMG: Severely aggressive children receiving stimulant medication versus stimulant and risperidone: 12-Month follow-up of the TOSCA trial. J Am Acad Child Adolesc Psychiatry, 55:469–478, 2016.
22.
JensenPS, BuitelaarJ, PandinaGJ, BinderC, HaasM: Management of psychiatric disorders in children and adolescents with atypical antipsychotics. Eur Child Adolesc Psychiatry, 16:104–120, 2007.
23.
KearnsMA, HawleyKM: Predictors of polypharmacy and off-label prescribing of psychotropic medications: A national survey of child and adolescent psychiatrists. J Psychiatr Pract, 20:438–447, 2014.
24.
KielingC, Baker-HenninghamH, BelferM, ContiG, ErtemI, OmigbodunO, RohdeLA, SrinathS, UlkuerN, RahmanA: Child and adolescent mental health worldwide: Evidence for action. Lancet, 378:1515–1525, 2011.
25.
KreiderAR, MatoneM, BellonciC, dosReisS, FeudtnerC, HuangYS, LocalioR, RubinDM: Growth in the concurrent use of antipsychotics with other psychotropic medications in Medicaid-enrolled children. J Am Acad Child Adolesc Psychiatry, 53:960–970.e962, 2014.
26.
LachaineJ, DeG, SikiricaV, Van StralenJ, HodgkinsP, YangH, HerouxJ, Ben AmorL: Treatment patterns, resource use, and economic outcomes associated with atypical antipsychotic prescriptions in children and adolescents with attention-deficit hyperactivity disorder in Quebec. Can J Psychiatry, 59:597–608, 2014.
27.
LarzelereRE, DingesK, SchmidtMD, et al.Outcomes of residential treatment: A study of the adolescent clients of girls and boys town. Child Youth Care Forum, 30:175–185, 2001.
28.
LiaoTV, PhanSV: Acute hyperglycemia associated with short-term use of atypical antipsychotic medications. Drugs, 74:183–194, 2014.
29.
LindsayRL, LeoneS, AmanMG: Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders. Clin Pediatr (Phila), 43:437–444, 2004.
30.
LongdenE, ReadJ: Assessing and reporting the adverse effects of antipsychotic medication: A systematic review of clinical studies, and prospective, retrospective, and cross-sectional research. Clin Neuropharmacol, 39:29–39, 2016.
31.
LoyJH, MerrySN, HetrickSE, StasiakK: Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev (9):CD008559, 2012.
32.
LyonsJS: Communimetrics: A Communication Theory of Measurement in Human Service Settings. New York, Springer, 2009.
33.
MannA, LiA, RadwanK, KarnikNS, KeenanK: Factors associated with management of teen aggression: Child psychiatric clinical decision making. J Child Adolesc Psychopharmacol, 27:445–450, 2017.
34.
MatoneM, LocalioR, HuangYS, dosReisS, FeudtnerC, RubinD: The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: A national study of U.S. Medicaid-enrolled children. Health Serv Res, 47:1836–1860, 2012.
35.
McHughRK, BarlowDH: The dissemination and implementation of evidence-based psychological treatments. A review of current efforts. Am Psychol, 65:73–84, 2010.
36.
MojtabaiR, OlfsonM: National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry, 67:26–36, 2010.
37.
MorenoC, Merchán-NaranjoJ, AlvarezM, BaezaI, AldaJA, Martínez-CantareroC, ParelladaM, SánchezB, de la SernaE, GiráldezM, ArangoC: Metabolic effects of second-generation antipsychotics in bipolar youth: Comparison with other psychotic and nonpsychotic diagnoses. Bipolar Disord, 12:172–184, 2010.
38.
MortimerAM: Adding a psychosocial intervention to antipsychotic medication reduces treatment discontinuation and relapse. Evid Based Ment Health, 14:24, 2011.
39.
NielsenJ, GraffC, KantersJK, ToftE, TaylorD, MeyerJM: Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs, 25:473–490, 2011.
40.
O'BrienC: Best practices in behavior support: Preventing and reducing the use of restraint and seclusion. Residential Group Care Q, 5, 2004. pp. 14–16.
41.
OlfsonM, BlancoC, LiuSM, WangS, CorrellCU: National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry, 69:1247–1256, 2012.
42.
OlfsonM, BlancoC, WangS, LajeG, CorrellCU: National trends in the mental health care of children, adolescents, and adults by office-based physicians. JAMA Psychiatry, 71:81, 2014.
43.
OlfsonM, KingM, SchoenbaumM: Treatment of young people with antipsychotic medications in the United States. JAMA Psychiatry, 72:867–874, 2015.
44.
PatelNC, HariparsadM, Matias-AktharM, SorterMT, BarzmanDH, MorrisonJA, StanfordKE, StrakowskiSM, DelBelloMP: Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics. J Child Adolesc Psychopharmacol, 17:303–311, 2007.
45.
PenfoldRB, StewartC, HunkelerEM, MaddenJM, CummingsJR, Owen-SmithAA, RossomRC, LuCY, LynchFL, WaitzfelderBE, ColemanKJ, AhmedaniBK, BeckAL, ZeberJE, SimonGE: Use of antipsychotic medications in pediatric populations: What do the data say?. Curr Psychiatry Rep, 15:426, 2013.
46.
PringsheimT, HirschL, GardnerD, GormanDA: The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: A systematic review and meta-analysis. Part 2: Antipsychotics and traditional mood stabilizers. Can J Psychiatry, 60:52–61, 2015.
47.
RawalPH, LyonsJS, MacIntyre IiJC, HunterJC: Regional variation and clinical indicators of antipsychotic use in residential treatment: A four-state comparison. J Behav Health Serv Res, 31:178–188, 2004.
48.
RoddayAM, ParsonsSK, CorrellCU, RobbAS, ZimaBT, SaundersTS, LeslieLK: Child and adolescent psychiatrists' attitudes and practices prescribing second generation antipsychotics. J Child Adolesc Psychopharmacol, 24:90–93, 2014.
49.
SikiricaV, PliszkaSR, BettsKA, HodgkinsP, SamuelsonTM, XieJ, ErderMH, DammermanRS, RobertsonB, WuEQ: Impact of atypical antipsychotic use among adolescents with attention-deficit/hyperactivity disorder. Am J Manag Care, 20:711–721, 2014.
50.
SohnM, MogaDC, BlumenscheinK, TalbertJ: National trends in off-label use of atypical antipsychotics in children and adolescents in the United States. Medicine (Baltimore), 95:e3784, 2016.
51.
SohnM, TalbertJ, BlumenscheinK, MogaDC: Atypical antipsychotic initiation and the risk of type II diabetes in children and adolescents. Pharmacoepidemiol Drug Saf, 24:583–591, 2015.
52.
Southam-GerowMA, WeiszJR, KendallPC: Youth with anxiety disorders in research and service clinics: Examining client differences and similarities. J Clin Child Adolesc Psychol, 32:375–385, 2003.
53.
TeixeiraEH, JacinthoA, CeleriHV, DalgalarrondoP: Atypical antipsychotics in the treatment of pathological aggression in children and adolescents: Literature review and clinical recommendations. Trends Psychiatry Psychother, 35:151–159, 2013.
54.
TroostPW, LahuisBE, SteenhuisMP, KetelaarsCE, BuitelaarJK, van EngelandH, ScahillL, MinderaaRB, HoekstraPJ: Long-term effects of risperidone in children with autism spectrum disorders: A placebo discontinuation study. J Am Acad Child Adolesc Psychiatry, 44:1137–1144, 2005.
55.
U.S. Department of Health and Human Services. Centers for Medicare and Medicaid Services. Atypical Antipsychotic Medications: Use in Pediatric Patients, October, 2015. (www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/).
56.
VitielloB, CorrellC, van Zwieten-BootB, ZuddasA, ParelladaM, ArangoC: Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol, 19:629–635, 2009.
57.
WeberSR, WehrAM, DucheminAM: Prevalence of antipsychotic prescriptions among patients with anxiety disorders treated in inpatient and outpatient psychiatric settings. J Affect Disord, 191:292–299, 2016.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
